Lyme Disease - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Lyme Disease - Pipeline Review, H1 2019’, provides an overview of the Lyme Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lyme Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lyme Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lyme Disease

- The report reviews pipeline therapeutics for Lyme Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Lyme Disease therapeutics and enlists all their major and minor projects

- The report assesses Lyme Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Lyme Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Lyme Disease

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Lyme Disease pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Inovio Pharmaceuticals Inc

NovoBiotic Pharmaceuticals LLC

Valneva SE

Inovio Pharmaceuticals Inc

NovoBiotic Pharmaceuticals LLC

Valneva SE

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Lyme Disease - Overview

Lyme Disease - Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Lyme Disease - Overview

Lyme Disease - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Lyme Disease - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Lyme Disease - Companies Involved in Therapeutics Development

Inovio Pharmaceuticals Inc

NovoBiotic Pharmaceuticals LLC

Valneva SE

Lyme Disease - Drug Profiles

azithromycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Inhibit CRASP1 for Lyme Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

desloratadine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Inhibit OspA for Lyme Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lyme disease vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lyme disease vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Outer Surface Protein A for Lyme Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Lyme Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Lyme Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VLA-15 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lyme Disease - Dormant Projects

Lyme Disease - Product Development Milestones

Featured News & Press Releases

Jan 31, 2019: VALNEVA reports positive initial booster data and final phase 1 data for its Lyme disease vaccine candidate

Dec 17, 2018: Valneva starts Phase ll trial of VLA15 to treat Lyme disease

Oct 25, 2018: VALNEVA receives positive feedback from EMA on its further development for Lyme disease vaccine VLA15

Jul 02, 2018: Valneva Announces Significant Progress of its Lyme Disease Vaccine Candidate

Mar 29, 2018: VALNEVA to Present on Lyme disease candidate VLA-15 at the 18th World Vaccine Congress in Washington, D.C.

Mar 19, 2018: VALNEVA Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidate VLA15

Jul 24, 2017: VALNEVA Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15

Dec 09, 2016: Valneva Receives FDA and European Approvals to Start Clinical Testing of Lyme Disease Vaccine Candidate

Jul 12, 2016: European Investment Bank Grants Valneva a EU25 Million Loan to Fund R&D Activities

Mar 24, 2016: VALNEVA to present at the 16th World Vaccine Congress in Washington D.C.

Jan 22, 2013: Agile Sciences Receives Grant From Bay Area Lyme Fund

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Lyme Disease, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Tables

Number of Products under Development for Lyme Disease, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Lyme Disease - Pipeline by Inovio Pharmaceuticals Inc, H1 2019

Lyme Disease - Pipeline by NovoBiotic Pharmaceuticals LLC, H1 2019

Lyme Disease - Pipeline by Valneva SE, H1 2019

Lyme Disease - Dormant Projects, H1 2019

List of Figures

List of Figures

Number of Products under Development for Lyme Disease, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Figures

Number of Products under Development for Lyme Disease, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports